A confirmatory pharmacokinetic study of OPNT-003
Phase of Trial: Phase II
Latest Information Update: 10 Sep 2018
At a glance
- Drugs Nalmefene (Primary)
- Indications Opioid abuse
- Focus Pharmacokinetics; Registrational
- Sponsors Opiant Pharmaceuticals
- 10 Sep 2018 According to an Opiant Pharmaceuticals media release, Opiant intends to initiate this trial in early 2019.
- 09 Aug 2018 According to an Opiant Pharmaceuticals media release, the company was recently awarded a grant of approximately $7.4 million from the National Institutes of Healths (NIH) which will be used to fund completion of registration study.
- 29 Jun 2018 New trial record